Sarepta announced positive topline three-year EMBARK results, showing that Alevidis significantly slowed disease progression on key functional measures in ambulatory Duchenne patients.Sarepta Therapeutics
Sarepta’s DMD gene therapy drives disease remission three years after treatmentbiospace
Sarepta’s Duchenne gene therapy slows disease progression in three yearsreuters
Sarepta Therapeutics will report 3-year topline data from the EMBARK study of Alevidis gene therapy in ambulatory individuals with Duchenne muscular dystrophy.business wire
Sarepta stock soars. 3-year study results bring hope for Elevidis.Baron’s
